Platform Start-Up Anaphore And Mitsubishi Tanabe Ink Deal For Autoimmune Therapies
This article was originally published in The Pink Sheet Daily
Executive Summary
Anaphore's novel Atrimer platform creates trivalent protein drugs to bind all three domains on trivalent ligands and receptors, a presumed advantage over two-armed antibodies.
You may also be interested in...
Variety Of Novel Approaches Marks Next-Gen Cancer Therapies At AACR
The annual meeting of the American Association for Cancer Research has always been a venue for biotechs to display innovative approaches to treating cancer – perhaps catching the eye of an investor – and the 2011 meeting didn't disappoint.
Variety Of Novel Approaches Marks Next-Gen Cancer Therapies At AACR
The annual meeting of the American Association for Cancer Research has always been a venue for biotechs to display innovative approaches to treating cancer – perhaps catching the eye of an investor – and the 2011 meeting didn't disappoint.
Japanese Pharma, Hungry For Global Deals, Can Fill Gap of Shrinking Partners - PharmAsia Summit
SAN FRANCISCO - The number of large Western pharmaceutical companies is shrinking due to M&A activity, and outward-looking Japanese firms of all sizes are quickly becoming an attractive option for biotechs looking for global and regional deals